DexCom Inc. (DXCM)
NASDAQ
Closed
Oct 9, 2026
Day's Range
82.9452 wk Range
54.11Overview - DXCM - DexCom Inc.
Key Statistics
Valuation
Enterprise Value
31.66B
P/E (Trailing)
‪33.73‬
P/E (Forward)
‪27.34‬
PEG Ratio
‪0.81‬
Price / Sales (TTM)
‪6.48‬
Price / Book
‪12.28‬
EV / EBITDA
‪22.56‬
Profitability
Gross Margin
‪63.43%‬
Profit Margin
‪20.11%‬
Operating Margin
‪24.32%‬
Return on Assets
‪10.33%‬
Return on Equity
‪38.49%‬
Ownership
Shares Outstanding
377.40M
Float
375.99M
Short % of Shares Outstanding
‪5.28%‬
Held by Insiders
‪0.26%‬
Held by Institutions
‪106.60%‬
Price stats
Beta
‪1.41‬
50-Day Avg
‪86.38‬
200-Day Avg
‪73.05‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
28 analysts
Average price target
‪$ 94.12‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - DXCM - DexCom Inc.
Peers - DXCM - DexCom Inc.
Peer Comparison
Compared with companies in Medical Devices listed on NASDAQ.
Profile Summary - DXCM - DexCom Inc.
About
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
